Adagene Inc. ADAG
1.71 USD -0.29 (-14.50%)
At closeNov 13, 2026, 4:00 PM EST
1.70 -0.01 -0.58%
After hours · Nov 13, 4:00 PM ET
1.70 Day range 1.96
1.53 52-week range 4.78
- YTD
- -9.52%
- 1 year
- -5.00%
News
benzinga.com Adagene Announces Completion Of Patient Enrollment In Its Phase 2 Study Of Muzastotug To Treat Microsatellite Stable Colorectal Cancer Without Liver Metastases Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced completion of…
globenewswire.com Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - Enrollment of 60 patients complete; initial results expected in 1H 2027 to inform dose regimen for the Phase 3 trial - Adagene continues to own worldwide commercial rights to muzastotug SAN DIEGO…
benzinga.com Adagene Doses First Patient In Phase 1 Study Evaluating Combination Of Muzastotug And INCA33890, Incyte’s TGFβR2 × PD-1 Bispecific Antibody, In Patients With Microsatellite Stable Colorectal Cancer Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver…
globenewswire.com Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte's TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver…
globenewswire.com Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and…
marketbeat.com Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer Adagene NASDAQ: ADAG is advancing its masked anti-CTLA-4 antibody, ADG126, also known as muzastotug, in metastatic microsatellite-stable colorectal cancer (MSS CRC) and in a neoadjuvant…
defenseworld.net Adagene (NASDAQ:ADAG) Stock Rating Reaffirmed as “Buy” by HC Wainwright Adagene (NASDAQ: ADAG - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Monday, MarketBeat.com reports. They presently…
defenseworld.net Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts Adagene (NASDAQ: ADAG) Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company's antibody pipeline, its approach to masked therapies and upcoming development…
marketbeat.com Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts Adagene NASDAQ: ADAG Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company's antibody pipeline, its approach to masked therapies and upcoming development milestones…
globenewswire.com Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel…
benzinga.com China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary…
globenewswire.com Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene's proprietary…
defenseworld.net Insider Buying: Adagene (NASDAQ:ADAG) CEO Acquires $63,913.50 in Stock Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) CEO Peter Luo acquired 20,290 shares of the business's stock in a transaction dated Wednesday, September 16th. The shares were acquired at…
seekingalpha.com Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
benzinga.com Third Arc Bio Selects First Lead Candidate Upon 2025 Amended Strategic License Deal With Adagene Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that…
globenewswire.com Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept.- benzinga.com Chardan Capital Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9 Chardan Capital analyst Gautam Chukka initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
globenewswire.com Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and…
globenewswire.com Adagene to Participate in Three Upcoming Investor Conferences SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel…
benzinga.com Adagene H1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $1.620M Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.10) by 100 percent. This is a 5.26 percent decrease over losses of $(0.19) per…
globenewswire.com Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen…
zacks.com Adagene (ADAG) Upgraded to Buy: Here's What You Should Know Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com Are Medical Stocks Lagging Adagene (ADAG) This Year? Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
marketbeat.com Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst…
globenewswire.com Adagene to Participate in Two Upcoming Investor Conferences SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based…
defenseworld.net Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Significant Growth in Short Interest Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling…
benzinga.com Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026 Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%,…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Guggenheim Maintains Buy on Adagene, Raises Price Target to $10 Guggenheim analyst Paul Jeng maintains Adagene (NASDAQ:ADAG) with a Buy and raises the price target from $9 to $10.
- benzinga.com Adagene Announces Results From Latest Data Cut From Phase 1b/2 Study Of Muzastotug In Patients With Advanced Microsatellite Stable Colorectal Cancer With No Liver Metastases Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement…
benzinga.com Adagene Collaborates With Incyte To Evaluate Combination Of Muzastotug And INCA33890 In Patients With Microsatellite Stable Colorectal Cancer With Or Without Liver Metastases Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastasesStudy will be sponsored and conducted by Incyte; Adagene to provide…- benzinga.com Adagene FY Adj. EPS $(0.24) Misses $(0.15) Estimate, Sales $7.671M Beat $1.667M Estimate Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.15) by 60 percent. This is a 52.94 percent increase over losses of $(0.51) per…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Adagene Announces Data Update From Ongoing Phase 1b/2 Study Of Muzastotug + Pembrolizumab In 3L+ MSS CRC Patients Remains On Track For Q1 2026 Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026Unaudited cash and cash equivalents of $74.5 million as of December 31,…- benzinga.com Guggenheim Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9 Guggenheim analyst Paul Jeng initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Adagene Says First Patient Dosed In Randomized, Open Label Phase 2 Study Of Muzastotug In Combination With Merck's Anti-PD-1 Therapy, KEYTRUDA In Patients With MSS CRC With No Liver Metastases Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDAPatients randomized to either 10 or 20 mg/kg of muzastotug,…- benzinga.com LUCID CAPITAL MARKETS Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9 LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Adagene, Lowers Price Target to $7 HC Wainwright & Co. analyst Arthur He maintains Adagene (NASDAQ:ADAG) with a Buy and lowers the price target from $8 to $7.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Adagene H1 Adj. EPS $(0.19) Beats $(0.34) Estimate Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.34) by 44.12 percent. This is a 26.92 percent increase over losses of $(0.26) per…
benzinga.com This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com Leerink Partners Initiates Coverage On Adagene with Outperform Rating, Announces Price Target of $7 Leerink Partners analyst Daina Graybosch initiates coverage on Adagene (NASDAQ:ADAG) with a Outperform rating and announces Price Target of $7.
- benzinga.com Sanofi Invests Up to $25M in Adagene to Advance Cancer Drug Trials Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced strategic investment and option exercise…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $8 Price Target HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $8 price target.
- benzinga.com Adagene Announces Investigator Initiated Phase 2 Trial For Neoadjuvant Muzastotug In Colorectal Cancer - Trial to begin enrolling in April; expected primary completion in mid-2027 -- Primary study endpoint of rate of major pathological response -SAN DIEGO and SUZHOU, China, Feb. 27, 2025 (GLOBE…
- benzinga.com HC Wainwright & Co. Maintains Buy on Adagene, Raises Price Target to $8 HC Wainwright & Co. analyst Arthur He maintains Adagene (NASDAQ:ADAG) with a Buy and raises the price target from $5 to $8.